PVLA · Palvella Therapeutics Inc
United States · RS rating 91 · As of 2026-11-03
| Price | 152.93 USD |
|---|---|
| 1-day change | +4.5% |
| RS rating (overall / 1M / 3M / 12M) | 91 / 90 / 64 / 93 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 44 / 56 / 38 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -26.7% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +3.3% |
| Market cap (USD) | $1.8B |